Product Name: OSR1 (182-188) pT185
Product Number: PE-04AOG99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: OSR1 (182-188) pT185

Product Use: Services as a blocking peptide for use with the OSR1-pT185 rabbit polyclonal antibody (Cat. No.: AB-PK738) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T185 phosphorylation timulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: VRK-pT-FVG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1059.17 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: OSR1 - pT185 phosphosite-specific antibody (Cat. No.: AB-PK738)

Scientific Background: OSR1 (OXSR1) is a protein-serine/threonine kinase of the STE group and STE20 family. It is activated by stress, and may mediate actin cytoskeleton rearrangement. Phosphorylation of OSR1 at T185 (in the kinase activation loop) and S325 are stimulatory for phosphotransferase activity. A K46A mutation in OSR1 led to the inhibition of autophosphorylation and it prevented activation of phosphotransferase activity. The K36M mutation was noted to prevent phosphorylation of RELT, RELL1, and RELL2, though it is possibility that other kinases in the solution may have been able to still generate a complex with OSR1. In gastric cancer, OSR1 is believed to be methylated in the promoter region inducing down-regulation of gene transcription, leading to disease. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.